Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Javelin Pharmaceuticals, Inc. ("Javelin" or the "Company") (AMEX: JAV) arising from the Company's announcement of its intent to be acquired by Myriad Pharmaceuticals ("Myriad"). Under the terms of the proposed transaction, Javelin shareholders will receive 0.282 shares of Myriad stock, or approximately $1.50, for each share of Javelin stock owned in a transaction with a total value of approximately $96 million. Javelin shareholders may receive an additional ownership interest depending upon the timing of FDA approval of Javelin's lead drug candidate Dyloject.

The investigation is focused on the potential unfairness of the price to Javelin shareholders and the process by which the Company's Board of Directors considered and approved the transaction. In particular, the price offered to Javelin shareholders appears to be considerably lower than the target price set by certain analysts of $3.50 per share of Javelin stock.

If you are interested in discussing your rights as a Javelin shareholder, or have information relating to this investigation, please contact Finkelstein Thompson's Washington, D.C. offices at (877) 337-1050 or by email at This email address is being protected from spam bots, you need Javascript enabled to view it .